14. Immunologic rheumatic disorders

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 2 SUPPL. 2, 2003, Pages

  Brasington Jr , Richard D ^a   Kahl, Leslie E ^a   Ranganathan, Prabha ^a   Latinis, Kevin M ^a   Velazquez, Celso ^a   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid syndrome; Dermatomyositis; Inclusion body myositis; Juvenile rheumatoid arthritis; Polymyositis; Rheumatoid arthritis; Scleroderma; Sj gren syndrome; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CEVIMELINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MUSCARINIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; CLINICAL FEATURE; DERMATOMYOSITIS; DRUG ACTIVITY; DRY EYE; HUMAN; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; NAUSEA; NONHUMAN; OCCUPATIONAL THERAPY; ORTHOPEDIC SURGERY; ORTHOTICS; PATHOGENESIS; PATIENT EDUCATION; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SKIN ATROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; VOMITING; XEROSTOMIA;

EID: 0037326533     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.79     Document Type: Review

References (21)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
3. Guidelines for the management of rheumatoid arthritis 2002 update. American College of Rheumatology subcommittee on rheumatoid arthritis guidelines. Arthritis Rheum 2002;46:328-46.
4. ACR ad hoc committee on SLE guideline. Guidelines for referral and management of SLE in adults. Arthritis Rheum 1999;42:1785-95.
5. Kavanaugh A, Tomar R, Reveille J, et al. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000;124:71-81.
6. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
8. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
9. Golan TD. Lupus vasculitis: differential diagnosis with antiphospholipid syndrome. Curr Rheumatol Rep 2002;4:18-24.
10. Hughes Syndrome: antiphospholipid syndrome. Khamashta MA, editor. London: Springer; 2000.
11. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207.
12. Valesini G, Priori R, Bavoillot D, Osborn J, Danieli MG, Del Papa N, et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997;24:2376-80.
13. Jonsson R, Haga H, Gordon T. Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand J Rheumatol 2000; 29:341-8.
14. Fox RI, Maruyama T. Pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1997;9:393-9.
15. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. Badesch DB, Tapson VF, McGoon MD. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized controlled trial. Ann Intern Med 2001; 132:425-34.
17. White B, Moore WC, Wigley FM. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
18. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;1991:1487-98.
19. Hengstman GJD, van Engelen BGM, Vree WTM. Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 2001;13:476-82.
20. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine (Baltimore) 1991;70:360-74.
21. Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002;41:7-13.